DG3173

Aspireo Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing novel therapies for orphan endocrine disorders. The company's primary asset was DG3173 (also known as somatoprim), a next-generation somatostatin analog (SSA) with a unique binding profile targeting somatostatin receptor subtypes 2, 4, and 5. This differentiated profile was designed to provide potent suppression of growth hormone and ACTH while minimizing the inhibitory effects on insulin secretion, potentially offering a superior safety and efficacy profile compared to first-generation SSAs. Aspireo targeted high-unmet-need conditions such as acromegaly and Cushing's disease. The company was acquired by Strongbridge Biopharma in 2015, and its assets are currently part of the Xeris Biopharma portfolio following a subsequent acquisition.